Literature DB >> 6603593

Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone.

A R Green, K O'Shaughnessy, M Hammond, M Schächter, D G Grahame-Smith.   

Abstract

The effect of pirenperone, a putative 5-HT2 receptor antagonist, on various 5-HT-mediated behavioural responses has been examined. The head twitch response in mice, induced by administration of carbidopa (25 mg/kg) followed by 5-hydroxytryptophan (5-HTP) (200 mg/kg), was inhibited in a dose-dependent manner by pirenperone, with an ED50 of 76 micrograms/kg. The appearance of head weaving, forepaw treading and hind-limb abduction, which followed the administration of tranylcypromine (5 mg/kg) plus L-tryptophan (100 mg/kg) or quipazine (50 mg/kg) to rats, was also inhibited by pretreatment with pirenperone (100 micrograms/kg). Pirenperone did not alter the rate of 5-HT synthesis in the rat brain. Whilst pirenperone (100 micrograms/kg) did decrease methamphetamine-induced locomotor activity in rats, a dose of haloperidol producing a similar inhibition of this response did not alter the 5-HT-mediated behaviour. It is suggested, therefore, that the currently used 5-HT-induced behavioural models are 5-HT2 receptor-mediated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6603593     DOI: 10.1016/0028-3908(83)90147-8

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  37 in total

1.  Involvement of 5-HT(3) receptors in the nucleus accumbens in the potentiation of cocaine-induced behaviours in the rat.

Authors:  S Herges; D A Taylor
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

Review 3.  The behavioral pharmacology of hallucinogens.

Authors:  William E Fantegrossi; Kevin S Murnane; Chad J Reissig
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

4.  Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist.

Authors:  A Doble; D Girdlestone; O Piot; D Allam; J Betschart; A Boireau; A Dupuy; C Guérémy; J Ménager; J L Zundel
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

5.  Effect of interferon-alpha on DOI-induced wet-dog shakes in rats.

Authors:  A Kugaya; A Kagaya; Y Uchitomi; N Yokota; S Yamawaki
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 6.  Serotonin 2A receptors are a stress response system: implications for post-traumatic stress disorder.

Authors:  Kevin Sean Murnane
Journal:  Behav Pharmacol       Date:  2019-04       Impact factor: 2.293

7.  Selective effects of pirenperone on analgesia produced by morphine or electrical stimulation at sites in the nucleus raphe magnus and periaqueductal gray.

Authors:  D Paul; A G Phillips
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

8.  Differential effects of serotonin 5-HT1A receptor agonists on the discriminative stimulus effects of the 5-HT2A receptor agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rats and rhesus monkeys.

Authors:  Jun-Xu Li; Wouter Koek; Kenner C Rice; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2010-01-06       Impact factor: 4.030

Review 9.  Tryptamine: a metabolite of tryptophan implicated in various neuropsychiatric disorders.

Authors:  D D Mousseau
Journal:  Metab Brain Dis       Date:  1993-03       Impact factor: 3.584

10.  5-HT2 receptor characteristics in frontal cortex and 5-HT2 receptor-mediated head-twitch behaviour following antidepressant treatment to mice.

Authors:  G M Goodwin; A R Green; P Johnson
Journal:  Br J Pharmacol       Date:  1984-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.